Judge Blows the Lid Off NIH Grant Cuts: Calls Out Unprecedented Discrimination!
A federal judge declared Monday that cancelling hundreds of research grants was unlawful. The ruling also raised concerns over potential racial bias in the process.
U.S. District Judge William Young of Massachusetts criticized the Trump administration’s approach as “arbitrary and capricious,” highlighting that they failed to adhere to established procedures when cancelling grants focused on gender identity or diversity, as well as equity and inclusion initiatives.
During the hearing, the judge requested a formal definition of Diversity, Equity, and Inclusion (DEI) and questioned how grants studying health disparities could be cut under these criteria.
Young, who was appointed by Republican President Ronald Reagan, identified a “darker aspect” behind the actions, accusing the government of racial discrimination and bias against the LGBTQ community.
He remarked, “I’ve never seen government racial discrimination like this in 40 years on the bench.” The hearing concluded with Young indicating he would soon issue a formal opinion.
The ruling covers only some of the NIH-funded projects that were targeted. The lawsuits, filed by groups including attorneys general and scientists, challenge the broader impact of the cancellations. The government is considering appeals or requesting a stay on the order.
NIH’s legal representatives argued that the grant terminations were justified, citing a broad discretion to align funding decisions with agency priorities. Meanwhile, some grants related to minority health and other research were either preserved or renewed, highlighting the selective nature of the cuts.
Federal officials stated that they are exploring legal options, including appealing the judge’s decision, while maintaining support for ending grants that they believe were ideological or scientifically unsubstantiated.
The lawsuits primarily dispute the use of “boilerplate” termination notices and argue that the research topics, ranging from cardiovascular studies to mental health, were valid and important for public health.
The scope of research affected was broad, including studies on heart disease, infectious diseases, mental health, and drug addiction, among others. Advocates warn that these cuts could harm research progress and public health outcomes.
Every morning, the NY POSTcast provides a deep dive into the headlines. Subscribe here!